表紙
市場調査レポート

体外診断(IVD)の世界市場 - 市場規模、シェア、世界動向、企業プロフィール、需要、考察、分析、調査、レポート、機会、セグメンテーションおよび予測

In Vitro Diagnostics (IVD) Market - Global Industry Analysis, Growth, Trends, Opportunities, Size, Share and Forecast, 2012 - 2020

発行 Allied Market Research 商品コード 305986
出版日 ページ情報 英文 152 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
体外診断(IVD)の世界市場 - 市場規模、シェア、世界動向、企業プロフィール、需要、考察、分析、調査、レポート、機会、セグメンテーションおよび予測 In Vitro Diagnostics (IVD) Market - Global Industry Analysis, Growth, Trends, Opportunities, Size, Share and Forecast, 2012 - 2020
出版日: 2014年06月14日 ページ情報: 英文 152 Pages
概要

体外診断(IVD)はヒトの体外の人工環境で試料検査を実施する診断技法であり、その世界市場規模は2013年時点で533億2000万ドル。これが以降数年にわたって5.34%の複合年間成長率から、2020年には746億5000万ドルに拡大する見通しです。

当レポートでは、体外診断の世界市場に注目し、今後の推移を技法、製品種、利用形態、用途、末端利用者、地域(北米、欧州、アジア太平洋州、その他)の別に分析・予測するほか、発展の推進・抑制要因・機会、技術研究、用途開発、競合環境、主要参入企業などについての最新情報を集めています。

第1章 イントロダクション

  • レポート内容
  • 主要市場セグメント
  • 調査方法
    • 二次情報調査
    • 一次情報取材
    • 分析ツールおよびモデル

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 重要所見
    • 体外診断市場への主要な影響要因
    • 有力投資ポケット
    • 成功への重要戦略
  • Poterのファイブフォース分析
  • 行政府規制
  • バリューチェーン分析
  • 事例研究
  • 重要技術動向
    • 医療自動化の技法
    • デジタル病理学の新興市場
    • オミクスと体外診断
    • 遺伝子検査と体外診断
    • ポイントオブケア試験
    • テーラーメイド医療で加速する成長
    • 新登場の診断技法と体外診断への影響
  • 市場動態
    • 推進要因
      • 多発化する慢性・感染性疾患
      • 体外診断の技術進歩
      • 低侵襲性技術の台頭
      • 行政府医療支出の拡大
      • テーラーメイド医療手法の人気上昇
    • 抑制要因
      • 不透明な医療報酬制度
      • きびしい規制政策
    • 機会
      • 外部委託の有望な機会
      • 新技術の収斂

第4章 体外診断の世界市場 - 技法別

  • 免疫測定・免疫化学
  • 血液学
  • 臨床化学
  • 凝析
  • 微生物学
  • 分子診断
  • ポイントオブケア診断
  • その他の臨床技法
    • 臨床遠心分離
    • 体組織診断
    • 試料処理装置
    • フローサイトメトリー
    • 細胞学

第5章 体外診断の世界市場 - 製品種別

  • 計器
  • 試薬
  • データ管理システムハードウェアおよびソフトウェア
  • サービス

第6章 体外診断の世界市場 - 利用形態別

  • ディスポーザブル体外診断器具
  • 再利用型体外診断器具

第7章 体外診断の世界市場 - 用途別

  • 感染性疾患
  • 糖尿病
  • がん・腫瘍
  • 心臓病
  • 自己免疫疾患
  • 腎臓病
  • 薬物検査
  • HIV・エイズ
  • その他

第8章 体外診断の世界市場 - 末端利用者別

  • 病院
  • 研究施設
  • 学術機関
  • ポイントオブケア試験
  • その他

第9章 体外診断の世界市場 - 地域別

  • 北米
  • 欧州
  • アジア太平洋州
  • その他

第10章 企業プロフィール(企業概要、寸見、業績、戦略的動きおよび展開、SWOT分析など)

  • Alere Inc
  • Biomerieux
  • Danaher Corporation.
  • Roche Diagnostics.
  • Becton Dickinson And Company
  • Bio-Rad Laboratories
  • Abbott Laboratories
  • Bayer AG.
  • Arkray Inc.
  • Sysmex
  • Johnson & Johnson
  • Siemens
目次
Product Code: ME 14336

In vitro diagnostics (IVD) is the technique of diagnostic test outside the human body in an artificial environment. The IVD market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. The global IVD market is segmented based on techniques, product type, usability, application, end user and geography (North America, Europe, Asia Pacific and Rest of World). Geographically, Asia Pacific is the fastest growing region and very opportune market that would generate highest revenue by 2020. Increase in the number of chronic and infectious diseases, and technological advancements are the major driving factors for the market. Widespread knowledge of healthcare & its benefits, and cost effectiveness are some top impacting factors of the global IVD market. The stringent regulatory policies and reimbursement issues are limiting the growth of the market. Furthermore, the rising demand for technologically advanced diagnosis devices and increased spending capabilities of consumers on health care provides huge potential for IVD in Asia Pacific market.

IVD Techniques Market Analysis

Global IVD techniques market is been segmented based on immunoassays, clinical chemistry, point of care, molecular diagnostics, hematology, coagulation, microbiology and other clinical techniques. Point of care is the highest revenue-generating segment in the overall IVD techniques market. Molecular diagnostics is the fastest growing technique in the in the overall IVD techniques market due to its ability to detect the primary cause of the disease accurately

IVD Product Type Market Analysis

The product type segment is been segmented based on instruments, reagents, data management systems and services. Instruments hold the highest market share in the global IVD market followed by reagents. Reagents market is also growing at a faster pace. As it is mostly used in various equipment and play a key role in the overall diagnosis process. Rise in the usage of diagnostic devices in which reagents are required for performing diagnosis tests, is the major factor that drives the product type market.

IVD Usability Market Analysis

Usability segment is classified as disposable and reusable IVD devices. Doctors and clinicians currently prefer disposable devices, to avoid infections. Still, reusable IVD device holds the largest revenue share in the global IVD usability market. Cost effectiveness as a benefit of reusable devices is driving the growth of usability market.

IVD Applications Market Analysis

The application area is segmented based on infectious diseases, diabetes, cancer/oncology, cardiology, autoimmune diseases, nephrology, drug testing, HIV/AIDS and others. Infectious diseases generated the highest revenue for current and forecast period mainly due to rise in the incidences of infectious diseases. HIV/AIDS application market is the second largest revenue generating applications segment and would remain the second largest through 2020.

IVD End User Market Analysis

Hospitals, laboratories, academics, point of care testing and others are the end users of global IVD market. Academic institutions provide trainings of IVD to the students. Laboratories generate the highest revenue followed by point of care for global end user market. Rise in the number of laboratories in Asia Pacific regions and increased awareness about health care and its benefits are contributing towards the growth of laboratories market, which in turn drives the global IVD end users market.

IVD Geography Market Analysis

The detailed analysis of the global IVD market is done in various regions such as North America, Europe, Asia Pacific and Rest of World. North America is the largest revenue generating region in all segments of global IVD market, whereas Asia Pacific region is fastest growing region amongst the regions studied.

IVD Competitive Analysis

The study of top ten players in the global market reveals strategies adopted to maintain their position in the competitive market. Strategic analysis of the top players reveals that market players are adopting product launch as their key developmental strategy in the market, as the market players are innovating novel products to expand their product line. Acquisitions and approvals are some additional strategies adopted by the companies in the market to enhance their services and expand their reach across the globe.

IVD High Level Analysis

The market exploration provides a clear view of global IVD market. Porter's five-force model helps in analyzing market players, new entrants in the market and the novel strategies adopted by them. In the current business scenario, IVD market has moderate bargaining power of supplier due to existence of brand loyalty. Varying product differentiation would lead to moderate buyers' bargaining. High entry barriers lead to lower threat of new entrants. Intersegment substitution leads to lower threat of Substitute. The value chain analysis reveals the key intermediaries involved in the supply chain. Raw material suppliers, medical device manufacturers, distributors, service providers and end users are the various stakeholders involved in the supply chain of IVD market.

Reason For Study

IVD is the oldest technique for diagnosis of the disease. With increase in incidences of chronic and infectious diseases and rise in healthcare awareness amongst patients, the market is opportunistic in different geographies. As there is a shift from traditional diagnostic devices to advanced diagnostic devices, IVD would prove to be a lucrative market in future.

KEY DELIVERABLES

  • Assessments are made according to the current business scenario and the future market trends are forecast for the period 2013-2020, with the base figures of the year 2013
  • The analysis gives a wider view of the global market including its market trends, market structure, limiting factors and opportunities for the market
  • Porter's five force's model helps in analyzing the potential of buyers & suppliers, and the competitive sketch of the market, which would guide the market players to develop strategies accordingly
  • The value chain analysis provides a systematic study on the key intermediaries involved, which would in turn help the stakeholders in the market to make appropriate strategies
  • The advantages of the market are analyzed to help the stakeholders identify the opportunistic areas in a comprehensive manner

KEY MARKET SEGMENTS

MARKET BY TECHNIQUES

  • Immunoassays
  • Clinical Chemistry
  • Point Of Care
  • Molecular Diagnostics
  • Hematology
  • Coagulation
  • Microbiology
  • Other clinical techniques

MARKET BY PRODUCT TYPE

  • Instruments
  • Reagents
  • Data management systems
  • Services

MARKET BY USABILITY

  • Disposable
  • Reusable

MARKET BY APPLICATIONS

  • Infectious Diseases
  • Diabetes
  • Cancer/Oncology
  • Cardiology
  • Autoimmune Diseases
  • Nephrology
  • Drug Testing
  • HIV/AIDS
  • Others

MARKET BY END USER

  • Hospitals
  • Laboratories
  • Academics
  • Point of Care Testing
  • Others

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • Rest of World

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Research methodology
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors for the in vitro diagnostic market
    • 3.2.2. Top investment pockets
    • 3.2.3. Top winning strategies
  • 3.3. Porter five forces model
    • 3.3.1. Brand loyalty leads to moderate bargaining power of supplier
    • 3.3.2. Varying product differentiation would lead to moderate bargaining power of buyers
    • 3.3.3. Low threat from new entrants due to high entry barriers
    • 3.3.4. Less intersegment substitution leads to lower threat Of substitute
    • 3.3.5. Moderate competitive rivalry
  • 3.4. Government regulations
  • 3.5. Value chain analysis
  • 3.6. Case studies
    • 3.6.1. Case Study 1: Positioning of new IVD Platform by Life Science
    • 3.6.2. Case Study 2: To enhance the operational capabilities of diagnostic chemistry system
  • 3.7. Key technology trends
    • 3.7.1. Medical automation technologies
    • 3.7.2. Emerging markets in digital pathology
    • 3.7.3. Omics and IVD
    • 3.7.4. Genetics tests and IVD
    • 3.7.5. Point of care testing:
    • 3.7.6. Personalized medicine propelling growth:
    • 3.7.7. Emerging diagnostic technologies and impact on IVD
  • 3.8. Market dynamics
    • 3.8.1. Drivers
      • 3.8.1.1. Increasing incidences of chronic and infectious diseases
      • 3.8.1.2. Technological advancements in IVD
      • 3.8.1.3. Emergence of minimal invasive technologies
      • 3.8.1.4. Increasing government expenditures on healthcare
      • 3.8.1.5. Increase in popularity personalized medicine approach
    • 3.8.2. Restraints
      • 3.8.2.1. Unclear reimbursement policies
      • 3.8.2.2. Stringent Regulatory policies
    • 3.8.3. Opportunities
      • 3.8.3.1. Potential Opportunities for outsourcing
      • 3.8.3.2. Convergence of new Technologies.

CHAPTER 4 - GLOBAL IVD MARKET BY TECHNIQUES

  • 4.1. Immunoassay/Immunochemistry
  • 4.2. Hematology
    • 4.2.1. High throughput analyzer
    • 4.2.2. Medium throughput analyzer
    • 4.2.3. Low throughput analyzer
  • 4.3. Clinical chemistry
    • 4.3.1. Urine chemistry analyzers
    • 4.3.2. Blood gas electrolyte analyzers
    • 4.3.3. Others
  • 4.4. Coagulation
  • 4.5. Microbiology
    • 4.5.1. Blood culture
    • 4.5.2. Pathological culture
    • 4.5.3. Identification & antibiotic susceptibility testing
    • 4.5.4. Others
  • 4.6. Molecular diagnostics
    • 4.6.1. Infectious diseases
    • 4.6.2. Oncology
    • 4.6.3. Genetic diseases
    • 4.6.4. Blood screening
    • 4.6.5. Others
  • 4.7. Point of care
  • 4.8. Other clinical techniques
    • 4.8.1. Clinical centrifuges
    • 4.8.2. Tissue diagnosis
    • 4.8.3. Sample processors
    • 4.8.4. Flow cytometry
    • 4.8.5. Cytology

CHAPTER 5 - GLOBAL IVD MARKET BY PRODUCT TYPE

  • 5.1. Instruments
  • 5.2. Reagents
  • 5.3. Data management system hardware/software
  • 5.4. Services

CHAPTER 6 - GLOBAL IVD MARKET BY USABILITY

  • 6.1. Disposable IVD devices
  • 6.2. Re-Usable IVD devices

CHAPTER 7 - GLOBAL IVD MARKET BY APPLICATION

  • 7.1. Infectious diseases
  • 7.2. Diabetes
  • 7.3. Cancer/Oncology
  • 7.4. Cardiology
  • 7.5. Autoimmune diseases
  • 7.6. Nephrology
  • 7.7. Drug testing
  • 7.8. HIV/AIDS
  • 7.9. Others

CHAPTER 8 - GLOBAL IVD MARKET BY END USERS

  • 8.1. Hospitals
  • 8.2. Laboratory
  • 8.3. Academics
  • 8.4. Point-of-Care Testing
  • 8.5. Others

CHAPTER 9 - GLOBAL IVD MARKET BY GEOGRAPHY

  • 9.1. North America
  • 9.2. Europe
  • 9.3. Asia Pacific
  • 9.4. RoW

CHAPTER 10 - COMPANY PROFILES

  • 10.1. Alere Inc
    • 10.1.1. Company overview
    • 10.1.2. Company snapshot
    • 10.1.3. Business performance
    • 10.1.4. Key Strategies and developments
    • 10.1.5. SWOT analysis of Alere
  • 10.2. Biomerieux
    • 10.2.1. Company overview
    • 10.2.2. Company snapshot
    • 10.2.3. Business performance
    • 10.2.4. Key Strategies and developments
      • 10.2.4.1. Primary STRATEGIES: APPROVAL
      • 10.2.4.2. Secondary strategies: Acquisition
    • 10.2.5. SWOT analysis of BioMerieux
  • 10.3. Danaher Corporation.
    • 10.3.1. Company overview
    • 10.3.2. Company snapshot
    • 10.3.3. Business performance
    • 10.3.4. Key Strategies and development
    • 10.3.5. SWOT analysis of Danaher
  • 10.4. Roche Diagnostics.
    • 10.4.1. Company overview
    • 10.4.2. Company snapshot
    • 10.4.3. Business performance
    • 10.4.4. Key Strategies and developments
    • 10.4.5. SWOT analysis of Roche
  • 10.5. Becton Dickinson And Company
    • 10.5.1. Company overview
    • 10.5.2. Company snapshot
    • 10.5.3. Business performance
    • 10.5.4. Key Strategies and development
      • 10.5.4.1. Primary strategies: product launch
      • 10.5.4.2. Secondary strategies: Acquisition and Approval
    • 10.5.5. SWOT analysis of Becton Dickinson and Company
  • 10.6. Bio-Rad Laboratories
    • 10.6.1. Company overview
    • 10.6.2. Company snapshot
    • 10.6.3. Business performance
    • 10.6.4. Key Strategies and developments
    • 10.6.5. SWOT analysis of Bio-Rad Laboratories
  • 10.7. Abbott Laboratories
    • 10.7.1. Company overview
    • 10.7.2. Company snapshot
    • 10.7.3. Business Performance
    • 10.7.4. Key Strategies and developments
    • 10.7.5. SWOT analysis of Abbott Laboratories
  • 10.8. Bayer AG.
    • 10.8.1. Company overview
    • 10.8.2. Company snapshot
    • 10.8.3. Business Performance
    • 10.8.4. Key Strategies and Development
    • 10.8.5. SWOT analysis of Bayer AG
  • 10.9. Arkray Inc.
    • 10.9.1. Company overview
    • 10.9.2. Company snapshot
    • 10.9.3. Key Strategies and development
      • 10.9.3.1. Primary strategies
      • 10.9.3.2. Secondary strategies
    • 10.9.4. SWOT analysis of Arkray
  • 10.10. Sysmex
    • 10.10.1. Company overview
    • 10.10.2. Company snapshot
    • 10.10.3. Business performance
    • 10.10.4. Key strategies and developments
      • 10.10.4.1. Primary strategies: partnership
      • 10.10.4.2. Secondary strategies: approval
    • 10.10.5. SWOT analysis of Sysmex
  • 10.11. Johnson & Johnson
    • 10.11.1. Company overview
    • 10.11.2. Company snapshot
    • 10.11.3. Business Performance
    • 10.11.4. Key Strategies and Development
      • 10.11.4.1. Primary strategies: partnership
      • 10.11.4.2. Secondary strategies
    • 10.11.5. SWOT analysis of Johnson & Johnson
  • 10.12. Siemens
    • 10.12.1. Company overview
    • 10.12.2. Company snapshot
    • 10.12.3. Business performance
    • 10.12.4. Key Strategies and development
    • 10.12.5. SWOT analysis of Siemens

LIST OF TABLES:

  • TABLE 1: IVD MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 2: PORTERS FIVE FORCES MODEL
  • TABLE 3: GLOBAL INCIDENCES OF DISEASES
  • TABLE 4: GLOBAL IVD MARKET BY TECHNIQUE, 2013-2020 ($BILLION)
  • TABLE 5: GLOBAL IMMUNOASSAY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 6: GLOBAL HEMATOLOGY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 7: GLOBAL CLINICAL CHEMISTRY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 8: GLOBAL COAGULATION TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 9: GLOBAL MICROBIOLOGY TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 10: GLOBAL MOLECULAR DIAGNOSTICS TECHNIQUE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 11: POINT OF CARE TECHNIQUE MARKET,2013-2020,($BILLION)
  • TABLE 12: GLOBAL OTHER TECHNIQUES MARKET BY GEOGRAPHY,: 2013.-.2020, -.($BILLION)
  • TABLE 13: GLOBAL IVD BY PRODUCT TYPE MARKET, 2013-2020 ($BILLION)
  • TABLE 14: GLOBAL INSTRUMENTS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 15: GLOBAL REAGENTS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 16: GLOBAL DATA MANAGEMENT SOFTWARE MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 17: GLOBAL SERVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 18: GLOBAL IVD USABILITY MARKET, 2013-2020 ($BILLION)
  • TABLE 19: GLOBAL IVD DISPOSABLE DEVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 20: GLOBAL IVD REUSABLE DEVICES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 21: LIST OF MANUFACTURERS WITH RE-USABLE IVD DEVICES
  • TABLE 22: GLOBAL IVD APPLICATIONS MARKET, 2013-2020 ($BILLION)
  • TABLE 23: GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 24: GLOBAL IVD DIABETES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 25: GLOBAL IVD CANCER/ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 26: GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 27: GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 28: GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY, 2013-2020,- ($BILLIONS)
  • TABLE 29: GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 30: GLOBAL IVD HIV/AIDS MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 31: GLOBAL IVD OTHER DISEASES MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 32: GLOBAL IVD MARKET BY END USER ,2013-2020,($BILLION)
  • TABLE 33: GLOBAL IVD HOSPITALS MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 34: GLOBAL IVD LABORATORY MARKET BY GEOGRAPHY,2013-2020,($BILLIONS)
  • TABLE 35: GLOBAL IVD ACADEMICS MARKET BY GEOGRAPHY, 2013- 2020 ($BILLIONS)
  • TABLE 36: GLOBAL IVD POINT OF CARE TESTING MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 37: GLOBAL IVD OTHER MARKET BY GEOGRAPHY, 2013-2020 ($BILLIONS)
  • TABLE 38: GLOBAL IVD MARKET BY GEOGRAPHY, 2013-2020 ($BILLION)
  • TABLE 39: GLOBAL IVD NORTH AMERICA MARKET, 2013-2020 ($BILLION)
  • TABLE 40: GLOBAL IVD EUROPE MARKET, 2013-2020 ($BILLION)
  • TABLE 41: GLOBAL IVD ASIA PACIFIC MARKET, 2013-2020 ($BILLION)
  • TABLE 42: GLOBAL IVD REST OF THE WORLD MARKET, 2013-2020 ($BILLION)
  • TABLE 43: ALERE COMPANY SNAPSHOT
  • TABLE 44: BIOMERIEUX COMPANY SNAPSHOT
  • TABLE 45: DANAHER COMPANY SNAPSHOT
  • TABLE 46: ROCHE COMPANY SNAPSHOT
  • TABLE 47: BECTON DICKINSON AND COMPANY SNAPSHOT
  • TABLE 48: BIO-RAD LABORATORIES SNAPSHOT
  • TABLE 49: ABBOTT LABORATORIES SNAPSHOT
  • TABLE 50: BAYER AG COMPANY SNAPSHOT
  • TABLE 51: ARKRAY COMPANY SNAPSHOT
  • TABLE 52: SYSMEX COMPANY SNAPSHOT
  • TABLE 53: JOHNSON & JOHNSON COMPANY SNAPSHOT
  • TABLE 54: SIEMENS COMPANY SNAPSHOT

LIST OF FIGURES:

  • FIG. 1: TOP IMPACTING FACTORS
  • FIG. 2: TOP INVESTMENT POCKETS OF IVD MARKET BY TECHNIQUES 2013-2020.
  • FIG. 3: TOP WINNING STRATEGIES
  • FIG. 4: TOP WINNING STRATEGIES
  • FIG. 5: VALUE CHAIN ANALYSIS FOR IVD MARKET
  • FIG. 6: KEY FINANCIALS OF ALERE BY SALES 2013
  • FIG. 7: KEY FINANCIALS OF NET REVENUE BY GEOGRAPHY 2013
  • FIG. 8: SWOT ANALYSIS OF ALERE
  • FIG. 9: KEY FINANCIALS OF BREAKDOWN OF SALES BY TECHNOLOGY
  • FIG. 10: KEY FINANCIALS OF BREAKDOWN OF SALES BY GEOGRAPHY
  • FIG. 11: SWOT ANALYSIS OF BIOMERIEUX
  • FIG. 12: KEY FINANCIALS OF DANAHER SALES BY SEGMENT 2013
  • FIG. 13: KEY FINANCIALS OF DANAHER SALES BY GEOGRAPHY 2013
  • FIG. 14: SWOT ANALYSIS OF DANAHER
  • FIG. 15: KEY FINANCIALS OF ROCHE REVENUES BY SEGMENT 2012
  • FIG. 16: KEY FINANCIALS OF ROCHE SALES BY GEOGRAPHY 2013
  • FIG. 17: SWOT ANALYSIS OF ROCHE
  • FIG. 18: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY REVENUES BY SEGMENT 2013
  • FIG. 19: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY SALES BY GEOGRAPHY 2013
  • FIG. 20: SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
  • FIG. 21: KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY SEGMENT 2013
  • FIG. 22: KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUES BY GEOGRAPHY 2013
  • FIG. 23: SWOT ANALYSIS OF BIO-RAD LABORATORIES
  • FIG. 24: KEY FINANCIALS OF ABBOTT LABORATORIES REVENUES BY SEGMENT 2013
  • FIG. 25: KEY FINANCIALS OF ABBOTT LABORATORIES REVENUES BY GEOGRAPHY 2013
  • FIG. 26: SWOT ANALYSIS OF ABBOTT LABORATORIES
  • FIG. 27: KEY FINANCIALS OF BAYER AG COMPANY REVENUES BY SEGMENT 2013
  • FIG. 28: SWOT ANALYSIS OF BAYER AG
  • FIG. 29: SWOT ANALYSIS OF ARKRAY
  • FIG. 30: KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY SEGMENT 2013
  • FIG. 31: KEY FINANCIALS OF SYSMEX COMPANY REVENUES BY GEOGRAPHY 2013
  • FIG. 32: SWOT ANALYSIS OF SYSMEX
  • FIG. 33: KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY SEGMENT 2013
  • FIG. 34: KEY FINANCIALS OF JOHNSON & JOHNSON COMPANY REVENUES BY GEOGRAPHY 2013
  • FIG. 35: SWOT ANALYSIS OF JOHNSON & JOHNSON
  • FIG. 36: KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY SEGMENT 2013
  • FIG. 37: KEY FINANCIALS OF SIEMENS COMPANY REVENUES BY GEOGRAPHY 2013
  • FIG. 38: SWOT ANALYSIS OF SIEMENS
Back to Top